Characterization of Neurophysiologic and Neurocognitive Biomarkers for Use in Genomic and Clinical Outcome Studies of Schizophrenia
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Endophenotypes are quantitative, laboratory-based measures representing intermediate links in the pathways between genetic variation and the clinical expression of a disorder. Ideal endophenotypes exhibit deficits in patients, are stable over time and across shifts in psychopathology, and are suitable for repeat testing. Unfortunately, many leading candidate endophenotypes in schizophrenia have not been fully characterized simultaneously in large cohorts of patients and controls across these properties. The objectives of this study were to characterize the extent to which widely-used neurophysiological and neurocognitive endophenotypes are: 1) associated with schizophrenia, 2) stable over time, independent of state-related changes, and 3) free of potential practice/maturation or differential attrition effects in schizophrenia patients (SZ) and nonpsychiatric comparison subjects (NCS). Stability of clinical and functional measures was also assessed. METHODS: Participants (SZ n = 341; NCS n = 205) completed a battery of neurophysiological (MMN, P3a, P50 and N100 indices, PPI, startle habituation, antisaccade), neurocognitive (WRAT-3 Reading, LNS-forward, LNS-reorder, WCST-64, CVLT-II). In addition, patients were rated on clinical symptom severity as well as functional capacity and status measures (GAF, UPSA, SOF). 223 subjects (SZ n = 163; NCS n = 58) returned for retesting after 1 year. RESULTS: Most neurophysiological and neurocognitive measures exhibited medium-to-large deficits in schizophrenia, moderate-to-substantial stability across the retest interval, and were independent of fluctuations in clinical status. Clinical symptoms and functional measures also exhibited substantial stability. A Longitudinal Endophenotype Ranking System (LERS) was created to rank neurophysiological and neurocognitive biomarkers according to their effect sizes across endophenotype criteria. CONCLUSIONS: The majority of neurophysiological and neurocognitive measures exhibited deficits in patients, stability over a 1-year interval and did not demonstrate practice or time effects supporting their use as endophenotypes in neural substrate and genomic studies. These measures hold promise for informing the "gene-to-phene gap" in schizophrenia research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
Gottesman, I. I., & Gould, T. D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.636 · Cited by 5,615
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422 · cited 1×
“With respect to the stability of clinical assessment measures, functional status and capacity are becoming more widespread in schizophrenia research. Following the MATRICS initiative”
BackgroundA Meta-Analysis of Cognitive Remediation in Schizophrenia
McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J., & Mueser, K. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060906 · Cited by 1,214
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919 · cited 2×
“In this context, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) expert panel has established criteria that are considered ‘‘essential’’ for measure selection in clinical trial studies designed to improve cognition in schizophrenia [16].”
BackgroundStability and Course of Neuropsychological Deficits in Schizophrenia
Heaton, R. K., Gladsjo, J. A., Palmer, B. W., Kuck, J., Marcotte, T. D., & Jeste, D. V. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.1.24 · Cited by 618 · cited 1×
“The long-term stability of many neurocognitive measures in schizophrenia outpatients appears to be well-established (e.g.,”
BackgroundMismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients
Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407 · cited 4×
“All subjects were carefully screened to ensure they had never experienced a neurologic insult, such as significant head trauma and/or loss of consciousness as per our established methods [24,28,29].”
MethodInfluentialSelf-citationWOODS, S., DELIS, D., SCOTT, J., KRAMER, J., & HOLDNACK, J. (2006) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2006.06.002 · Cited by 401 · cited 1×
“In addition, each measure has independently been the focus of intense scientific inquiry that has, in some cases, produced a rich literature describing informative animal models with predictive and construct validity [55] and detailed underlying neural and molecular substrates [3,56].”
BackgroundGlutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371 · cited 1×
“Increasingly, these and other neurophysiological and neurocognitive measures are used as biomarkers in clinical trials for ‘‘proof of concept’’ studies designed to determine whether a drug has a detectable ‘‘neurobiological signal’’ or as outcome measures to determine if a drug improves cognition [10–15].”
BackgroundGreenwood, T. A., Lazzeroni, L. C., Murray, S. S., Cadenhead, K. S., Calkins, M. E., Dobie, D. J., Green, M. F., Gur, R. E., Gur, R. C., Hardiman, G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10050723 · Cited by 257 · cited 4×
“Future studies are needed to assess the utility of these measures for predicting conversion to psychosis, as biomarkers of response to pharmacologic and nonpharmacologic [74,84] treatments, for tracking disease progression across the course of illness [80], and for the delineation of schizophrenia-related abnormalitie…”
BackgroundMethodInfluentialSelf-citationHall, M.-H., Schulze, K., Rijsdijk, F., Kalidindi, S., McDonald, C., Bramon, E., Murray, R. M., & Sham, P. (2009) · Psychological Medicine · doi:10.1017/s0033291709005261 · Cited by 117 · cited 1×
“Related studies have confirmed that many of these measures show significant deficits in clinically unaffected relatives of schizophrenia patients, are heritable and informative for the identification of genetic variation in schizophrenia [3,7,22,54].”
Background
Cited by
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Erickson, M. A., Ruffle, A., & Gold, J. M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.025 · Cited by 426
Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia
Javitt, D. C., & Freedman, R. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13121691 · Cited by 403
Candidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4002 · Cited by 367
Cognition in schizophrenia: Past, present, and future
Green, M. F., & Harvey, P. D. (2014) · Schizophrenia Research: Cognition · doi:10.1016/j.scog.2014.02.001 · Cited by 258
Reduced Prepulse Inhibition as a Biomarker of Schizophrenia
Mena, A., Ruiz-Salas, J. C., Puentes, A., Dorado, I., Ruiz-Veguilla, M., & De la Casa, L. G. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00202 · Cited by 202
“In particular, Gottesman and Gould (2003) have proposed that PPI may be considered a schizophrenia endophenotype, that is, a subtype of biomarker that reflects the link between genetic and clinical expression (see, also, Turetsky et al., 2007; Light et al., 2012).”
BackgroundOxytocin׳s role in anxiety: A critical appraisal
MacDonald, K., & Feifel, D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.025 · Cited by 139
Kantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123
“…1990′s and have been replicated extensively since that time (Erickson et al., 2015; Friedman et al., 2012; Green et al., 2012; Javitt et al., 2008b; Light et al., 2012; Light et al., 2014; Umbricht and Krljes, 2005), and tied to poor functional outcome in schizophrenia (Jahshan et al., 2013;…”
BackgroundMethodPerez, V. B., Tarasenko, M., Miyakoshi, M., Pianka, S. T., Makeig, S. D., Braff, D. L., Swerdlow, N. R., & Light, G. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.25 · Cited by 94
Self-citationMismatch negativity (MMN) as a tool for translational investigations into early psychosis: A review
Tada, M., Kirihara, K., Mizutani, S., Uka, T., Kunii, N., Koshiyama, D., Fujioka, M., Usui, K., Nagai, T., Araki, T., et al. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.02.009 · Cited by 74
Kim, M., Kim, S. N., Lee, S., Byun, M. S., Shin, K. S., Park, H. Y., Jang, J. H., & Kwon, J. S. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.02.012 · Cited by 46
“Several studies have reported that changes in MMN are not correlated with changes in clinical symptoms (Light et al., 2012) and that MMN does not appear to be influenced by antipsychotic medications (Umbricht et al.”
McCleery, A., Mathalon, D. H., Wynn, J. K., Roach, B. J., Hellemann, G. S., Marder, S. R., & Green, M. F. (2019) · Psychological Medicine · doi:10.1017/s0033291718004087 · Cited by 35
“non-roving) paradigms have previously been shown to have moderate-to-good test-retest reliability in SZ (Light and Braff, 2005; Hall et al., 2006; Lew et al., 2007; Light et al., 2012; Biagianti et al., 2017).”
BackgroundThe effect of deviance predictability on mismatch negativity in schizophrenia patients
Horacek, M., Kärgel, C., Scherbaum, N., & Müller, B. W. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.010 · Cited by 9
“Reviews have established these findings to a degree that includes the consideration of MMN amplitude reductions as a biomarker and endophenotype of schizophrenia with relations to symptoms, cognition and global functioning [3, 4, 11, 15, 32].”
Background
Metadata
- Authors
- Light, G. A., Swerdlow, N. R., Rissling, A. J., Radant, A., Sugar, C. A., Sprock, J., Pela, M., Geyer, M. A., & Braff, D. L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-03
- Volume
- 7
- Issue
- 7
- Pages
- e39434
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2169619011
- Cited by
- 189
- References
- 13
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.